Skip to content
2000
  1. Home
  2. A-Z Publications
  3. New Emirates Medical Journal
  4. Fast Track Articles
  5. Fast Track Article
image of Protective Role of Vitamin C and Silymarin Against Olanzapine-Induced Hepatotoxicity in Albino Rats: A Histopathological and Biochemical Study
file format pdf download PDF

Abstract

Background:

Olanzapine is an atypical antipsychotic drug for treating bipolar disorders and Schizophrenia. Regardless of being used as a common antipsychotic drug, there are reports of hepatic abnormalities caused by using Olanzapine. Silymarin and Vitamin C have been shown to have hepatoprotective effects.

Objective:

The purpose of the present was to study the hepatotoxic effects of Olanzapine and the hepatoprotective role of Silymarin and Vitamin C on the Liver of Albino rats.

Methods:

The study was conducted on 24 albino rats. The animals were randomly divided into four groups of six rats each: Group A consisted of six rats and served as the control group; Group B consisted of six rats who received orally 4mg/kg of Olanzapine daily; Group C consisted of six rats who received 4mg/kg of Olanzapine plus 200mg/kg of Silymarin daily and Group D consisted of six rats which received orally 4mg/kg of Olanzapine plus 15mg/kg of Vitamin C daily. The animals were sacrificed in two sittings at four and eight weeks, and tissues were processed by routine histopathological technique. The liver enzymes (AST, ALP, ALT) were calculated and analyzed statistically using one-way ANOVA.

Results:

It was found that the liver of rats treated with Olanzapine showed sinusoidal dilatation, sinusoidal congestion, central venous congestion, central venous dilatation, cellular infiltration, and portal triaditis. The liver enzymes (AST, ALP, ALT) were markedly raised in the drug-treated rats, showing Olanzapine as a hepatotoxic agent. On the other hand, Silymarin and Vitamin C) both proved to show an excellent hepatoprotective effect.

Conclusion:

Olanzapine administration causes histopathological and biochemical abnormalities in the liver. Vitamin C and Silymarin are both potent hepatoprotective agents against Olanzapine-induced hepatic toxicity.

2024 © 2024 The Author(s). Published by Bentham Science Publisher. The Author(s)
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/nemj/10.2174/0102506882324343241217083414
2024-12-24
2025-01-31

  • From This Site

    /content/journals/nemj/10.2174/0102506882324343241217083414
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/nemj/10.2174/0102506882324343241217083414/e02506882324343.html?itemId=/content/journals/nemj/10.2174/0102506882324343241217083414&mimeType=html&fmt=ahah

References

  1. Pocock G. Richards C.D. Richards D.A. Human Physiology. 3rd ed Oxford University Press Oxford, UK 2006
    [Google Scholar]
  2. Mitchell M. Riesenberg R. Bari M.A. Marquez E. Kurtz D. Falk D. Hardy T. Taylor C.C. Mitchell C.P. Cavazzoni P. A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects. Clin. Ther. 2006 28 6 881 892 10.1016/j.clinthera.2006.06.008 16860171
    [Google Scholar]
  3. De Abagjo F.J. Montero D. Madurga M. Garcia Rodriguez L.A. Medication reviews in the community: Results of a randomized, controlled effectiveness trial. Br. J. Clin. Pharmacol. 58 6 648 664 2004 10.1111/j.1365‑2125.2004.02220.x 15563363
    [Google Scholar]
  4. Kolpe M. Ravasia S. Effect of olanzapine on the liver transaminases. Can. J. Psychiatry 2003 48 3 210 10.1177/070674370304800313 12728748
    [Google Scholar]
  5. Larry D. Ripault M.P. Hepatotoxicity of psychotropic drugs and drugs of abuse. Drug-induced liver disease. 3rd ed Kaplowitz N. DeLeve L.D. Amsterdam Elsevier 2013 443 462 10.1016/B978‑0‑12‑387817‑5.00025‑X
    [Google Scholar]
  6. Schrieber S.J. Wen Z. Vourvahis M. Smith P.C. Fried M.W. Kashuba A.D.M. Hawke R.L. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab. Dispos. 2008 36 9 1909 1916 10.1124/dmd.107.019604 18566043
    [Google Scholar]
  7. Parés A. Planas R. Torres M. Caballería J. Viver J.M. Acero D. Panés J. Rigau J. Santos J. Rodés J. Effects of silymarin in alcoholic patients with cirrhosis of the liver: Results of a controlled, double-blind, randomized and multicenter trial. J. Hepatol. 1998 28 4 615 621 10.1016/S0168‑8278(98)80285‑7 9566830
    [Google Scholar]
  8. Pradhan S.C. Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J. Med. Res. 2006 124 5 491 504 17213517
    [Google Scholar]
  9. Mahli A. Koch A. Czech B. Peterburs P. Lechner A. Haunschild J. Müller M. Hellerbrand C. Hepatoprotective effect of oral application of a silymarin extract in carbon tetrachloride-induced hepatotoxicity in rats. Clinical Phytoscience 2015 1 1 5 10.1186/s40816‑015‑0006‑z
    [Google Scholar]
  10. Salamone F. Galvano F. Cappello F. Mangiameli A. Barbagallo I. Li Volti G. Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. Transl. Res. 2012 159 6 477 486 10.1016/j.trsl.2011.12.003 22633099
    [Google Scholar]
  11. Solhi H. Ghahremani R. Kazemifar A.M. Hoseini Yazdi Z. Silymarin in treatment of non-alcoholic steatohepatitis: A randomized clinical trial. Caspian J. Intern. Med. 2014 5 1 9 12 24490006
    [Google Scholar]
  12. Tveden-Nyborg P. Lykkesfeldt J. Does vitamin C deficiency increase lifestyle-associated vascular disease progression? Evidence based on experimental and clinical studies. Antioxid. Redox Sign. 2013 19 17 2084 2104 10.1089/ars.2013.5382 23642093
    [Google Scholar]
  13. Das K.K. Gupta A.D. Dhundasi S.A. Patil A.M. Das S.N. Ambekar J.G. Effect of L-ascorbic acid on nickel-induced alterations in serum lipid profiles and liver histopathology in rats. J. Basic Clin. Physiol. Pharmacol. 2006 17 1 29 44 10.1515/JBCPP.2006.17.1.29 16639878
    [Google Scholar]
  14. Bhat G.M. Shah N.A. Shah B.A. Shahdad S. Itoo M.S. Maqdoomi M.A. Lithium carbonate induced histological changes in the Liver of Albino Rats. IOSR J. Pharm. Biol. Sci. 2014 45 48 9 3 10.9790/3008‑09314548
    [Google Scholar]
  15. Copeland R.A. Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis. John Wiley and Sons 2023 10.1002/9781119793304
    [Google Scholar]
  16. Bashandy S.A. AlWasel S.H. Carbon tetrachloride-induced hepatotoxicity and nephrotoxicity in rats: Protective role of vitamin C. J. Pharmacol. Toxicol. 2011 6 3 283 292 10.3923/jpt.2011.283.292
    [Google Scholar]
  17. Luft B. Taylor D. A review of atypical antipsychotic drugs versus conventional medication in schizophrenia. Expert Opin. Pharmacother. 2006 7 13 1739 1748 10.1517/14656566.7.13.1739 16925501
    [Google Scholar]
  18. Sikich L. Maloney Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients. Neuropsychiatr. Dis. Treat. 2010 6 749 766 10.2147/NDT.S6614 21127693
    [Google Scholar]
  19. Elbakary R. Histological study of effect of Olanzapine on liver of albino rats with and without vitamin C. Egypt. J. Histol. 2017 40 1 1 11 10.21608/EJH.2017.3692
    [Google Scholar]
  20. Shah R. Subhan F. Ali G. Ullah I. Ullah S. Shahid M. Ahmad N. Fawad K. Olanzapine induced biochemical and histopathological changes after its chronic administration in rats. Saudi Pharm. J. 2016 24 6 698 704 10.1016/j.jsps.2015.06.006 27829813
    [Google Scholar]
  21. Mateen S. Raina K. Agarwal R. Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer. Nutr. Cancer 2013 65 suppl. 1 3 11 10.1080/01635581.2013.785004 23682778
    [Google Scholar]
  22. Saller R. Melzer J. Reichling J. Brignoli R. Meier R. An updated systematic review of the pharmacology of silymarin. Complement. Med. Res. 2007 14 2 70 80 10.1159/000100581 17464157
    [Google Scholar]
  23. Wu J.W. Lin L.C. Tsai T.H. Drug–drug interactions of silymarin on the perspective of pharmacokinetics. J. Ethnopharmacol. 2009 121 2 185 193 10.1016/j.jep.2008.10.036 19041708
    [Google Scholar]
  24. Gillessen A. Schmidt H.H.J. Silymarin as supportive treatment in liver diseases: A narrative review. Adv. Ther. 2020 37 4 1279 1301 10.1007/s12325‑020‑01251‑y 32065376
    [Google Scholar]
  25. Aghaei F. Wong A. Zargani M. Sarshin A. Feizolahi F. Derakhshan Z. Hashemi M. Arabzadeh E. Effects of swimming exercise combined with silymarin and vitamin C supplementation on hepatic inflammation, oxidative stress, and histopathology in elderly rats with high-fat diet-induced liver damage. Nutrition 2023 115 112167 10.1016/j.nut.2023.112167 37611505
    [Google Scholar]
  26. He Z. Li X. Yang H. Wu P. Wang S. Cao D. Guo X. Xu Z. Gao J. Zhang W. Luo X. Effects of oral vitamin C supplementation on liver health and associated parameters in patients with non-alcoholic fatty liver disease: A randomized clinical trial. Front. Nutr. 2021 8 745609 10.3389/fnut.2021.745609 34595203
    [Google Scholar]
  27. Sabiu S. Sunmonu T.O. Ajani E.O. Ajiboye T.O. Combined administration of silymarin and vitamin C stalls acetaminophen-mediated hepatic oxidative insults in Wistar rats. Rev. Bras. Farmacogn. 2015 25 1 29 34 10.1016/j.bjp.2014.11.012
    [Google Scholar]
  28. Khaldoun Oularbi H. Richeval C. Lebaili N. Zerrouki-Daoudi N. Baha M. Djennas N. Allorge D. Ameliorative effect of vitamin C against hepatotoxicity induced by emamectin benzoate in rats. Hum. Exp. Toxicol. 2017 36 7 709 717 10.1177/0960327116661022 27461011
    [Google Scholar]
  29. Smirnoff N. Wheeler G.L. Ascorbic acid in plants: Biosynthesis and function. Crit. Rev. Plant Sci. 2000 19 4 267 290 10.1080/07352680091139231
    [Google Scholar]
  30. Rebouche C.J. Ascorbic acid and carnitine biosynthesis. Am. J. Clin. Nutr. 1991 54 Suppl. 6 1147S 1152S 10.1093/ajcn/54.6.1147s 1962562
    [Google Scholar]
  31. Curcio A. Romano A. Cuozzo S. Di Nicola A. Grassi O. Schiaroli D. Nocera G.F. Pironti M. Silymarin in combination with vitamin C, vitamin E, coenzyme Q10 and selenomethionine to improve liver enzymes and blood lipid profile in NAFLD patients. Medicina (Kaunas) 2020 56 10 544 10.3390/medicina56100544 33080906
    [Google Scholar]
/content/journals/nemj/10.2174/0102506882324343241217083414
Loading
Protective Role of Vitamin C and Silymarin Against Olanzapine-Induced Hepatotoxicity in Albino Rats: A Histopathological and Biochemical Study
Bentham Science Publishers , e02506882324343; https://doi.org/10.2174/0102506882324343241217083414
/content/journals/nemj/10.2174/0102506882324343241217083414
/content/journals/nemj/10.2174/0102506882324343241217083414
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: Sinusoidal dilatation ; Vitamin C ; Sinusoidal congestion ; Silymarin ; Olanzapine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test